Can GLP-1 drugs improve breast cancer survival?
Yes. In this large study of 841,831 women with stage I to III breast cancer, those who took GLP-1 drugs like Ozempic had a 65% lower risk of dying over 10 years if they had obesity, and a 56% lower risk of the cancer coming back. Among women with type 2 diabetes, GLP-1 drugs performed better than insulin or metformin on both measures, though not better than SGLT2 inhibitors.
GLP-1 drugs are a newer class of medication. They include semaglutide (Ozempic, Wegovy) and similar drugs. Doctors first used them to treat type 2 diabetes. Now they are also used for weight loss. This study looked at whether these drugs might also help women who have been diagnosed with breast cancer.
The research team pulled records from the TriNetX US Collaborative Network, a database that links de-identified patient charts from many hospitals across 68 health care organizations. They identified 841,831 women diagnosed with stage I, II, or III breast cancer between April 2006 and April 2023, with a mean age of 69.1 years. Then they used propensity score matching to build three comparison groups: 1,610 women with obesity comparing GLP-1 use to nonuse, 2,323 women with type 2 diabetes comparing GLP-1 drugs to insulin or metformin, and 4,052 women with type 2 diabetes comparing GLP-1 drugs to SGLT2 inhibitors.
What the data show
Among women with obesity, those who took GLP-1 drugs had a hazard ratio of 0.35 (95% CI, 0.21 to 0.58) for death from any cause, meaning a 65% lower risk over 10 years compared with matched women not on these drugs. Their risk of the cancer coming back fell by 56%, with a hazard ratio of 0.44 (95% CI, 0.30 to 0.64).
In women with type 2 diabetes, the comparison was against other diabetes drugs rather than against no drug at all. Compared with women treated with insulin or metformin, those on GLP-1 drugs had a hazard ratio of 0.09 (95% CI, 0.06 to 0.15) for death and 0.33 (95% CI, 0.21 to 0.50) for recurrence-free survival.
The third comparison is the one I would read most carefully. Against SGLT2 inhibitors, another modern diabetes drug class, there were no significant differences in either outcome. The landmark analyses put those hazard ratios at 1.09 (95% CI, 0.84 to 1.41) for death and 1.02 (95% CI, 0.80 to 1.31) for recurrence at 6 months, essentially flat. The authors describe the diabetes findings as similar to the obesity findings, not larger, and the different comparison groups mean these hazard ratios cannot be lined up against each other as a ranking of benefit.
Dr. Kumar’s Take
I want to be honest with you about how I read this paper. The size of the benefit here, especially in the insulin or metformin comparison, is so large that my first reaction is skepticism. A hazard ratio of 0.09 is the kind of number that almost never holds up once you run a real randomized trial. It usually shrinks. Sometimes it disappears.
The comparison against SGLT2 inhibitors is what keeps me grounded. When GLP-1 drugs are matched against a similarly modern diabetes medication, the difference vanishes. That pattern is what I would expect if a good part of the apparent benefit reflects who gets prescribed which drug rather than what the drug does to a tumor.
That said, the biology is plausible. Obesity and high insulin levels are known drivers of breast cancer growth, and GLP-1 drugs lower weight, blood sugar, and insulin all at once. The authors also point to preclinical work showing GLP-1 drugs inhibiting tumor growth, including in breast cancer. So a real effect would not surprise me. I just suspect the true effect is smaller than what this study shows. I want randomized trials before anyone starts a GLP-1 drug specifically to fight cancer, and the authors say the same thing.
How strong is the evidence?
This was a retrospective cohort study, which means the researchers looked back at electronic health records that already existed. They did not assign women to take GLP-1 drugs or not. That matters. Women who get prescribed these medications tend to be different from women who do not, in ways that can affect survival. They may be more engaged with their doctors, have better insurance, or be healthier overall in ways the database cannot capture.
Propensity score matching was used to balance the groups, and it worked reasonably well on most measured characteristics. One imbalance survived matching: overweight and obesity diagnoses remained far more common in the GLP-1 groups, at 34.8% versus 17.8% in the obesity comparison and 42.9% versus 26.1% in the insulin or metformin comparison. Matching can only balance what is recorded in the chart, and it can never fully erase the differences it does not see.
The authors frame their own conclusion carefully. They describe a potential association between GLP-1 use and improved outcomes, and they call for randomized clinical trials to evaluate the question properly.
Who might benefit most
If the effect is real, the women most likely to benefit are those who already have a reason to take a GLP-1 drug. That means women with type 2 diabetes, women with obesity, or women whose doctors are considering one of these medications for weight management. For those patients, the possibility of a cancer benefit is something to weigh alongside the known effects on blood sugar and weight.
For women without diabetes or obesity, this study does not justify starting a GLP-1 drug to lower cancer risk. The study only looked at women who had obesity or type 2 diabetes, so it says nothing about anyone else. The risk-benefit math only makes sense when there is already a clear reason to take the medication.
Practical Takeaways
- If you have been diagnosed with breast cancer and you also have type 2 diabetes or obesity, ask your oncologist and endocrinologist whether a GLP-1 drug might fit into your treatment plan for those conditions.
- Do not stop or change any cancer treatment based on this study, since GLP-1 drugs are not a substitute for standard breast cancer care like surgery, radiation, hormone therapy, or chemotherapy.
- Keep in mind that the 65% and 56% reductions reported here come from an observational study, so the true effect is likely smaller and will need randomized trials to confirm.
- If you are already taking an SGLT2 inhibitor for diabetes, note that this study found no survival or recurrence difference between that drug class and GLP-1 drugs.
- If you are already taking a GLP-1 drug for weight or diabetes, this is one more reason to stay engaged with your primary care doctor and cancer screening schedule.
Related Studies and Research
- Women’s Health Initiative: what 20 years of follow-up really shows about HRT and breast cancer
- Omega-3 fatty acids and type 2 diabetes risk: what the latest research reveals
- Coffee reduces mortality risk: prospective cohort evidence
- Enough: why the WHI continues to misrepresent its own breast cancer data
FAQs
Should women with breast cancer ask their doctor about starting a GLP-1 drug?
Not based on this study alone. GLP-1 drugs like Ozempic and Wegovy are approved for type 2 diabetes and obesity, not for cancer treatment. If you have one of those conditions and also have breast cancer, it is a reasonable conversation to have with your oncologist and endocrinologist together. If you do not have diabetes or obesity, this study did not include women like you, and there is no evidence here that justifies the side effects and cost of these drugs for cancer prevention. Randomized trials are needed first.
Why might GLP-1 drugs help with breast cancer in the first place?
The leading idea is that obesity and high insulin levels feed breast cancer growth. GLP-1 drugs lower body weight, reduce insulin levels, and improve blood sugar control, all of which could in theory slow tumor growth or recurrence. The authors also cite preclinical studies in which GLP-1 drugs inhibited tumor growth in certain cancers, including breast cancer. None of this is proven in humans yet, but the biology is consistent with the observed pattern.
How confident should I be in a hazard ratio of 0.09 for death?
You should be cautious. Effect sizes that large in observational studies almost always shrink when researchers run a randomized trial. The most likely reason is that women prescribed GLP-1 drugs differ from women who are not, in many small ways that add up. Those differences, called confounders, can make a treatment look much better than it really is. The fact that GLP-1 drugs showed no advantage over SGLT2 inhibitors in this same study reinforces that caution. Read 0.09 as a signal worth investigating, not as a confirmed effect.
Bottom Line
In a database study of more than 800,000 women with stage I to III breast cancer, those who took GLP-1 drugs had lower rates of death and cancer recurrence over 10 years, both among women with obesity and among women with type 2 diabetes taking insulin or metformin. Against SGLT2 inhibitors, there was no difference. The signal is large enough to take seriously, especially given the plausible biology linking obesity, insulin, and breast cancer. But observational studies cannot prove cause and effect, and the size of the benefit will likely shrink in randomized trials. For now, GLP-1 drugs remain a treatment for diabetes and obesity, with a promising and unproven side benefit that deserves rigorous testing.
